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Abstract
The HIV pandemic persists globally and travelers are at risk for infection by the Human Immunodeficiency Virus (HIV).
While HIV-focused guidelines delineate risk stratification and mitigation strategies for people in their home communities,
travel issues are not addressed. In this review, direct and indirect evidence on HIV risk among travelers is explored. The
burgeoning practice of employing pre-exposure prophylaxis (PrEP) with anti-retroviral therapy in the non-travel setting is
introduced, as well as the more established use of post-exposure prophylaxis (PEP). Challenges in applying these lessons
to travelers are discussed, and a new guidelines process is scoped and recommended.
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Background
Pre-exposure prophylaxis (PrEP) against the Human
Immunodeficiency Virus (HIV) has been recommended
in several guidelines for persons at risk within their
home communities [1–3]. However, these guidelines
have ignored the use of PrEP in travelers, despite the
high frequency of travel both within the US and to even
more HIV endemic areas. According to a travel trade as-
sociation, in 2015, U.S. residents spent nearly 2.2 billion
person-days traveling in the US more than 50 miles from
their homes and using paid lodging [4]. In that same
year, more than 350,000 U.S. residents went to Africa,
4.8 million to Asia, 7.7 million to the Caribbean and
12.6 million to Europe [5]. As this readership appreci-
ates, travel affects behaviors and exposures, shaping
risks. Here, we will explore the current options for PrEP
against HIV infection and consider them in the context
of travel medicine.
What is the travel associated risk for HIV?
The GeoSentinel international surveillance network of
travel clinics assessed sexually transmitted infections (STI)
among its ill presenting returned travelers [6]. Among 299
men and 122 women with STI, 89 and 27, respectively, had
acute HIV infection. A patient with an antiretroviral syn-
drome might be induced to present disproportionately to
their travel medicine provider because of undifferentiated
fever. Also, for pathogens like HIV which can infect people
globally, GeoSentinel cannot exclude that patients
contracted their STI after returning home. Nonetheless,
across their cohort, STI morbidity was 6.6 per 1000 ill trav-
elers, more than a quarter of which was HIV infection.
That rate of HIV infection is nearly ten times lower than
the usual universal HIV testing threshold for prevalence
among presenting patients of one per cent. However, this
network demonstrates that travel-associated HIV infection
occurs. Passive, travel clinic case collection is just as likely
to underestimate HIV infection rates as most other clinical
care settings. In a large, recent study of acute HIV infection
in East Africa and Thailand, patients were just as likely to
not have symptoms as have them [7].
Despite awareness campaigns against supporting human
trafficking through use of commercial sex, some travelers
travel for sex [8]. Locations wildly differ in the degree to
which such settings are regulated and in the health con-
trols applied. Sexual tourism in particular presents a sig-
nificant risk for HIV exposure and acquisition. Among
UK-born adults diagnosed with HIV infection between
2002 and 2010 in England, Wales, and Northern Ireland,
15% were determined to have acquired infections outside
of the U.K. These individuals most commonly traveled to
the Thailand, the U.S., and South Africa and were more
likely than those who acquired HIV infections in the U.K.
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to have heterosexual exposures and to have reported
sexual contact with a commercial sex worker [9].
A number of studies have shown a positive association
between travel and risky behaviors. Historical rates of
casual sex exposure among travelers range as high as
50% [10]. In a survey of over 2,000 backpackers in
Thailand, 2 in 3 were single and young—two thirds of
respondents were under the age of 25—and mostly from
Europe [11]. Of those who were single, more than a
third reported having sex with a new partner. This was
true more often for men and men were more likely to
have sex with local persons. Longer length of stay was
associated with more risk behavior. Condom use was
variable. A survey of over 1,000 travelers from the U.K.
visiting a wide variety of locales obtained similar results,
though as might be expected the general travel popula-
tion was older than the backpackers [12].
Travelers presenting for health advice on the cusp
of or while working as emergency responders or
long term stay humanitarian workers present special
challenges. Given the numbers of persons who
undertake such work, STI risks and outcomes may
be underreported. A cross-sectional study of HIV
risk behavior among over 1,200 globally distributed
Peace Corps volunteers was undertaken in 1991 [13].
One in three single men and one in five single
women had three or more sexual partners during
their tours. A sero-survey of 864 Dutch expatriates
was conducted in the mid-1990s [14]. One in four of
those surveyed reported having unprotected sex with
a local person but only two HIV infections were
identified. A systematic review of pre-health advice
for recent humanitarian workers identified high rates
of unprotected sex, high alcohol use, depression,
acute stress reaction and other HIV/ STI risk factors
[15, 16].
A specialized population that may have travel associated
sexual health risks is that of military personnel around the
time of deployment. In a retrospective assessment of the
U.S. Navy and Marine Corps HIV epidemic, nearly 1 in 10
HIV infected Sailors and Marines reported that an
impending deployment contributed to their becoming in-
fected with HIV [17]. In this same study, vacation as a risk
factor for their having acquired HIV infection was cited by
1 in 5, and traveling for temporary assignment by 1 in 6.
Peri-deployment samples captured incident cases [18].
This also was observed in an investigation of U.S. Army
soldiers who had deployed to Afghanistan and Iraq [19].
However, both a subsequent study that explored HIV risk
factors in the context of U.S. Air Force airmen mobility
(deployments, duty station changes) and an internal
soldier-airman case control study determined that having
had increasing numbers of deployments was protective
against HIV acquisition [20].
How are antiretroviral medications used for prophylaxis?
Antiretroviral therapy (ART), or highly active antiretroviral
therapy (HAART)
Most medications used in antiretroviral therapy against
HIV infection target viral enzymes, in particular reverse
transcriptase, protease or integrase. Increasingly, ART med-
ications that block cellular receptors needed by the virus
are being used. Figure 1 depicts the HIV life cycle in a cell
and shows how ART drug classes apply to combating the
Fig. 1 Mechanisms of anti-HIV activity by drug class
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virus. Highly active antiretroviral therapy (HAART) refers
to the combination of ART medications employed together
for treatment of HIV in infected persons. The nomencla-
ture reflects the evolution of therapy from single agent in
the early years of the HIV pandemic to use of three and
four drug combinations as the ease with which HIV de-
velops resistance came to be understood. Both international
and country-level guidelines exist for HAART [21].
Careful review of side effects and use characteristics is
important, particularly when these medications are not
part of a provider’s usual practice. Comorbid conditions
such as renal disease and viral hepatitis influence the
choice of antiretroviral regimens. Many ART medications
have significant interactions with other drugs through the
induction and inhibition of metabolic pathways. Several
ART:anti-malarial medication interactions are cited in the
Yellow Book [22]. For instance, efavirenz decreases serum
concentration of atovaquone, co-formulated with progua-
nil in the anti-malarial medication Malarone®. A variety of
fee-based and open resources for assessing drug inter-
action risks also are available to help guide a provider’s
choice of treatments [23–25].
Pre-exposure prophylaxis (PrEP)
PrEP is pre-exposure prophylaxis for individuals who are
not HIV infected but carry above average risk for be-
coming infected with HIV. The most discussed and
available form of PrEP is oral antiretroviral therapy.
The first medication for which the Food and Drug
Administration (FDA) approved an indication for PrEP was
TRUVADA® [26]. It is a combination therapy of emtricita-
bine (a nucleoside analog, FTC) and tenofovir disoproxil
fumarate (a nucleotide analog, TDF) that inhibits the viral
enzyme reverse transcriptase. It is taken once daily as a sin-
gle tablet. While the mutability of HIV and, consequently,
increasing drug resistance rates have driven recommended
treatment courses to triple drug therapies, recommenda-
tions for prophylaxis have remained simple and narrow.
Table 1 compares the different guideline recommendations.
While the guidelines do not focus on the travel clinic
setting, they provide representative sexual health question-
naires and suggested criteria for both men who have sex
with men (MSM) and heterosexually active men and
women for determining who merits PrEP. These focus on
identifying patients at increased risk because of lack of
condom use, multiple sexual partners, history of sexually
transmitted infections or relationships with known HIV
positive partners.
Both FTC and TDF are globally distributed and consti-
tute the backbone of some first line HIV treatment
regimens. Should contraindications to these medications
exist, there are no recommended pharmacologic alterna-
tives in the setting of pre-exposure prophylaxis. Rather,
risk modifying behavior is indicated. Contraindications to
TDF include renal disease (e.g., creatinine clearance below
60 mL/min), osteopenia and osteoporosis. In the United
States, in single formulations for 30 tablets (one tablet per
day), FTC currently costs $643.82 and TDF $1,197.32.
Their co-formulation is similarly priced at $1,759.73 [27].
Research is underway for a variety of alternative PrEP
strategies that use both established HIV treatment medica-
tions and other approaches. The CCR5 receptor antagonist
maraviroc and the non-nucleoside reverse transcriptase in-
hibitor (NNRTI) dapirivine are being explored as a PrEP
option, both as the sole regimen and also in combination
with non-HIV medications delivered in a vaginal ring or va-
ginally applied tablets [28–30]. Vaginal delivery of FTC and
TDF also are being assessed [31, 32]. An injectable, depot
formulation of the integrase strand transfer inhibitor cabo-
tegravir has a 40 day elimination half life. A comparison is
planned between it and TDF + FTC as PrEP [33, 34]. A
similar trial is in progress for a high dose, every 8 week ad-
ministration of the injectable rilpirivine, a NNRTI [35, 36].
Biologic agents such as broadly neutralizing monoclonal
antibodies and small molecule inhibitors also may find a
niche for this indication [37].
Post-exposure prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is taken following a po-
tential HIV exposure. Guidelines for its use are divided
into two categories, occupational PEP (oPEP) and non-
occupational PEP (nPEP) [38–40]. Experience with PEP
is much more robust than that with PrEP. Uncertainty
regarding its effectiveness under ideal circumstances as
well as how long after an exposure initiating PEP still
brings benefit leaves it an incomplete solution [3, 41].
Early guidelines advocated a risk tiered approach where
low risk exposures employed two NRTI, higher risk ex-
posures were an indication for the addition of a PI. Now,
at least three-drug therapy is recommended (Table 1)
[42]. Certain scenarios trigger a recommendation for ex-
pert consultation. These include when use is delayed,
unknown sources of infection, pregnancy, breast-feeding,
suspected viral resistance, toxicity of the initial regimen,
serious comorbidities [42]. Suspicion or confirmation of
viral hepatitis is another setting where expert consult-
ation is prudent for PrEP, nPEP and oPEP. nPEP and
oPEP are taken for 28 days.
Who is using PrEP in their communities and to what effect?
As recommendations on use of PrEP become increasingly
liberal, impact on patient and community risks is a matter
for prospective study. However, success has been demon-
strated in several key high-risk populations. A 2012
Cochrane review assessed four completed, randomized,
controlled clinical trials that tested TDF + FTC in high-
risk groups [43]. Among nearly 9,000 pooled participants,
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Table 1 Current options for pharmacologic prophylaxis against HIVa,b
Medication Dose (mg) Frequency Comments Guidelines
Pre-Exposure Prophylaxis (PrEP) CDC WHO IAS
TDF + FTC 300/ 200 Daily TDF- Nausea, flatulence FTC- rash, headache; distinguish from the
treatment co-formulation with efavirenz
X X X
TDF 300 Daily Not recommended alone in the US; whether in combination











RAL- Mild hepatitis is common, and hypersensitivity, severe skin
reactions have been reported though more common side effects
include fatigue, headache, dizziness, nausea and insomnia
Alternative recommendation for health adults and adolescents is




+ either LPV/r or ATV/r
300/ 200
Varies












The core recommendation is to take 3 or more tolerable drugs;
listed alternatives for TDF + FTC include ZDV + 3TC; listed alternatives
for RAL include DRV/r, ETR, RPV, ATZ/r, LPV/r; listed alternative for




+ either LPV/r or ATV/r
300/ 200
Varies
Daily Alternatives for the 3rd drug on the TDF + FTC backbone include
RAL, DRV/r, EFV
WHO guidelines do not distinguish nPEP and oPEP
X
ATV Atazanavir, DRV Darunavir, DTG Dolutegravir, EVG Elvitegravir, ETR Etravirine, FTC Emtricitabine, 3TC Lamivudine, LPV Lopinivir, RAL Raltegravir, RPV Rilpivirine, RTV Ritonavir, /r boosting with ritonavir, TDF Tenofovir
disoproxil fumarate, TDF + FTC available taken together as separate tablets or in co-formulation, ZDV Zidovudine
For post-exposure prophylaxis, IAS defers to CDC. The CDC produces the nPEP recommendations, while the United States Public Health Service (PHS) generated the oPEP recommendations
aIndividual patient contraindications including drug:drug interactions, pregnancy, infections, chronic diseases such as renal or hepatic disease. They must be considered with each use. Providers should use
applicable guidelines














the relative risk (RR) of HIV infection for those on PrEP
was 0.51 (95%CI 0.3-0.86). TDF alone also attenuated risk
among 4,000 participants yielding a greater risk reduction,
RR 0.38 (95%CI 0.23-0.63).
The results of practical application of PrEP in public
health programs for some populations have been pub-
lished. In a demonstration project on PrEP linked to sexu-
ally transmitted infection (STI) clinics in San Francisco
and Miami, and a community health center in Washing-
ton DC, 557 men who have sex with men (MSM) and
transgender women were followed for 48 weeks [44]. On
study entry, almost 1 in 4 participants reported that their
primary partner was HIV infected—typically on antiretro-
viral therapy—but most had additional partners. Adher-
ence was almost 90% in San Francisco and Washington
DC, but 65% in Miami. In addition to location, risk factors
for poor adherence based upon dried blood spot TDF
levels were being African American, and not renting or
owning their own dwelling. Those with 2 or more
episodes of unprotected receptive anal intercourse in the
previous 3 months had higher rates of adherence. STI
prevalence was high at time of screening, declined at
24 weeks but then increased again by 48 weeks. Nonethe-
less, only 2 HIV incident infections were observed. As
these communities were selected because of an annual
HIV incidence of 2% or higher, this suggests a substantial
protective effect despite inevitable enrollment biases.
Whether that protection is attributable only to reductions
of risk at the individual level, or the presence of a collect-
ive effect because of decreased transmission within social
networks is not clear.
Another open label, STI clinic-linked PrEP imple-
mentation project across 13 sites in England random-
ized 544 MSM participants to immediate or 1 year
deferred treatment groups [45]. As in the project by Liu
et al, TDF + FTC was used. The immediate PrEP group
experienced 3 incident HIV infections, in contrast to 20
in the deferred PrEP group. Of these 20, 17 had been
infected prior to the onset of PrEP, and the other 3 may
have been. Post-exposure prophylaxis of TDF + FTC +
lopinavir, a protease inhibitor (PI), was administered to
85 participants in the deferred group, 22 of which
received three or more courses. Of the 20 deferred
PrEP incident cases, 6 of the patients had received
post-exposure prophylaxis in 12 courses of treatment.
The authors estimated a number need to treat of 13—1
year of PrEP in 13 men of this population would
prevent one incident case of HIV infection. As in the
U.S. PrEP implementation project, STI rates were high
and unperturbed.
Trials to assess PrEP adoption and use, patient and
social network protective efficacy are underway now in
developing areas that have particular stigma against
some high-risk groups [46]. Cohorts also exist
examining use among heterosexual women in Africa
[47]. Studies among commercial sex workers for PrEP
have focused on willingness to adopt surveys [48, 49].
Although, some clinical care site-based cohorts such as
The Combine! Study in Brazil may incorporate more
commercial sex workers than had previous studies [50].
The emergence and consequences of resistant HIV as-
sociated with long term PrEP remain unclear and an
area for study [51].
Counseling the traveler on HIV risk and PrEP
The most secure methods to prevent HIV acquisition are
risk modifying behaviors—abstinence, appropriate con-
dom use, knowledge of HIV status in self and partners
and clean needle use. These should be reinforced in the
course of travel counseling even if opting to use PrEP.
Travel clinics should routinely assess sexual health risks in
their patient assessments and counseling. Travel-related
risks associated with HIV infection should be elicited in
the pre-travel evaluation in order to identify anticipated
exposures and risks associated with travel in addition to
baseline, non-travel risk. For those who might benefit
from long term PrEP use, the travel medicine visit should
be used as an opportunity to encourage patients to discuss
PrEP with their primary physician. For those with short-
term risks, consider provision of non-occupational post-
exposure prophylaxis (nPEP) medications and instructions
on their use after a high-risk, non-occupational exposure
in accordance with guidelines.
Currently, consensus guidelines do not exist to guide the
unique decisions about offering PrEP to travelers who are
not already taking it for pre-existing risk factors in their
home communities. For the long-term stay travelers (i.e.,
months to years) the guidelines can be used to discuss
established risk profiles in the context of the impending liv-
ing environment. Per country HIV prevalence rates for
some at risk areas are listed in the WHO Global Health
Observatory data repository [52]. For short-term stay trav-
elers (i.e., days to weeks), their usual risk and contexts can
be reassessed in order to determine if baseline PrEP use
ought to be considered. Studies have not tested the
pharmacodynamics, adherence and efficacy of short term
PrEP. If attempting to use PrEP for travel-related risk, a
traveler may have to initiate it one to two weeks prior to
travel. Pre-prescription assessments of renal function, HIV
and viral hepatitis status would be prudent, as well as re-
view of the medical history for renal disease and osteopenia.
Insofar as possible, current guidelines for PrEP manage-
ment should be followed. Monitoring issues will exist. For
long-term travelers, in country support would have to be
considered. To what degree insurance would cover episodic
PrEP use for travel is not clear. Ideally, short-term travelers
will incorporate their primary care providers in these dis-
cussions also as their risk may need to be reassessed.
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Conclusions and ways ahead
Key summary points are listed below.
As technologies for PrEP improve, its application in
the traveler may become simpler. Depot injections that
can be applied regardless of baseline health status, for
instance, would be welcome. Regardless, PrEP use in the
traveler, as PrEP use in communities, carries manage-
ment and policy issues that merit attention. Travel and
HIV interested professional societies and bodies should
consider convening a dedicated review and guidelines
process for this issue. Some travelers that may not be
good candidates for long term PrEP could benefit from
episodic, short-term PrEP associated with travel, should
safe and effective approaches for this use be agreed.
Should such a guidelines effort be undertaken, several
considerations useful to travel medicine providers require
focused attention. These include PrEP evaluation for eligi-
bility, minimum screening labs, PrEP initiation, toxicity
monitoring, discontinuation/transition to nPEP, HIV epi-
demiology and resistance, and impacts upon risk reduc-
tion counseling. Both the way level of HIV risk is
addressed in PrEP guidelines and the potential different
sexual health risks present among varying types of travel
and traveler also need to be considered. Travel medicine
services are provided in a variety of settings and by a range
of providers. This includes primary care providers, infec-
tious diseases specialists, stand-alone travel medicine
clinics and comprehensive travel medicine clinics inte-
grated in infectious diseases and preventive medicine
clinics. Knowledge regarding PrEP is associated with clin-
ical experience using PrEP and ART prescribing experi-
ence [53–55]. Ideally, patients present 4–6 weeks prior to
travel for evaluation by a travel medicine provider. How-
ever, patients often present much more proximal to antici-
pated departure and require expedited evaluation,
couseling, and interventions. The lead time required to
achieve protective drug levels in serum, rectal, and vaginal
tissues is not entirely known. Limited existing pharmaco-
kinetic data suggest that 7 and 20 days are required for
protection at rectal tissue and cervico-vaginal tissues, re-
spectively [56–59]. Thus, significant challenges are present
in managing and counseling patients about risk and risk
mitigation strategies depending on specific travel related
sexual risk exposures such as insertive penile sex and re-
ceptive vaginal and anal sexual exposures and the incom-
plete knowledge of the estimated time to achieve
protection in relevant tissues. Specific practical guidance
for the travel medicine provider should include recom-
mendations for consideration of PrEP initiation for last
minute travelers with imminent travel and for transition-
ing travelers from PrEP to nPEP for those travelers in
whom pre-travel PrEP duration may have been inadequate
to achieve maximum protection. Additionally, some trav-
elers may be healthcare workers for who occupational
post-exposure prophylaxis (oPEP) needs may be present.
These considerations add to the need for and complexity
of a guidelines process.
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